Related Experiment Video
Updated: Jun 27, 2026
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Ning Lou1,2, Ruyun Gao3, Yuankai Shi4
1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College; No.1, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Abstract:
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the latest and a vital treatment option for non-small cell lung cancer (NSCLC) patients. Although EGFR-sensitive mutations are an indication for third-generation EGFR-TKI therapy, 30% of NSCLC patients lack response and all patients inevitably progress. There is a lack of biomarkers to predict the efficacy of EGFR-TKI therapy. In this report, we performed comprehensive plasma metabolomic profiling on 186 baseline and 20 post-treatment samples, analyzing 1,019 metabolites using four ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) methods. The dataset contains detailed clinical and metabolic information for 186 patients. Rigorous quality control measures were implemented. No significant differences in body mass index and biochemical metabolic parameters were observed between responders and non-responders. The datasets were utilized to characterize the responsive metabolic traits of third-generation EGFR-TKI therapy. All datasets are available for download on the OMIX website. We anticipate that these datasets will serve as valuable resources for future studies investigating NSCLC metabolism and for the development of personalized therapeutic strategies.
Insights
Third-generation EGFR-TKIs show promise for non-small cell lung cancer (NSCLC). This study profiles plasma metabolites to identify biomarkers for predicting treatment response in NSCLC patients.
Area of Science:
- Oncology
- Metabolomics
- Pharmacogenomics
Background:
- Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are crucial for non-small cell lung cancer (NSCLC).
- A significant portion of NSCLC patients exhibit resistance or inevitable progression despite EGFR-sensitive mutations.
- Biomarkers for predicting EGFR-TKI efficacy are currently lacking.
Purpose of the Study:
- To perform comprehensive plasma metabolomic profiling in NSCLC patients treated with third-generation EGFR-TKIs.
- To identify metabolic traits associated with treatment response.
- To create a valuable dataset for future research in NSCLC metabolism and personalized therapy.
Main Methods:
- Plasma metabolomic profiling of 186 baseline and 20 post-treatment samples.
- Analysis of 1,019 metabolites using four ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) methods.
- Rigorous quality control and clinical data integration.
Main Results:
- No significant differences in BMI or standard biochemical metabolic parameters between responders and non-responders.
- Characterization of responsive metabolic traits associated with third-generation EGFR-TKI therapy.
- Comprehensive dataset including clinical and metabolic information for 186 patients.
Conclusions:
- The study provides a valuable, high-quality dataset for investigating NSCLC metabolism.
- Identified metabolic traits may aid in predicting response to third-generation EGFR-TKI therapy.
- The data can facilitate the development of personalized therapeutic strategies for NSCLC.
